Clinical trial Recruiting at 3 sites Observational Ages 18 to 90

Brain PET scan with [18F]NIDF to see tau protein in Alzheimer’s and other tau-related diseases

Official title: [18F]NIDF PET Imaging in Tau-related Diseases

Run by Tianjin Medical University · NCT07306598 · Data updated 2026-11-12

We are testing whether a new PET tracer called [18F]NIDF can safely show tau protein in the brains of healthy adults and people with Alzheimer’s disease or other tauopathies.

More Alzheimer's Disease trials

Quick facts

Study typeObservational
Ages18 Years to 90 Years
SexAll
Enrollment20 (estimated)
SponsorTianjin Medical University
Academic / other
Locations3 sites (Hefei, Anhui and 2 other locations)
StatusRecruiting
StartedNovember 1, 2025
Main results expectedDecember 1, 2030
Study endsDecember 1, 2030
Registry record updatedSeptember 8, 2026
Trial IDNCT07306598 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–90 who can give informed consent (or have a legal representative), including healthy controls and people with probable Alzheimer’s disease or other causes of dementia, are eligible if they have no other neurological diseases and can tolerate PET procedures.

Probably not a fit

People who cannot consent, are allergic to the tracer or its excipients, are unwilling or unable to undergo PET scans, or have major medical conditions that interfere with imaging or safety may not benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational imaging project uses the radioactive tracer [18F]NIDF injected before PET scanning to visualize abnormal tau neurofibrillary tangles in living human brains. The tracer is a 2-arene-azaindole-based compound designed for stronger tau binding and reduced off-target signal compared with existing tau PET agents. Adult participants (ages 18–90), including healthy volunteers and people with probable Alzheimer’s or other dementias, will be enrolled and undergo tracer injection and PET imaging at participating hospitals. The primary focus is on imaging safety and how well the tracer highlights tau pathology for diagnostic use.

Why it matters

Potential benefit: If successful, this tracer could improve the accuracy and clarity of tau imaging, helping doctors detect and track Alzheimer’s and other tauopathies earlier and more reliably.

How similar studies have gone: Other tau PET tracers have been used successfully in research and clinical settings, but [18F]NIDF is a newer agent claiming stronger tau binding and less off-target uptake and is being tested clinically.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Between 18 and 90 years old;
2. No gender limitation;
3. Clinical diagnositic rerults supported the diagnosis of neurodegeneration, and there was no evidence of other neurological diseases;
4. Healthy participants or patients with probable Alzheimer's disease or with dementia due to other causes;
5. Informed consent signed in person by the subject or his legal guardian or caregiver.

Exclusion Criteria:

1. Has allergy to \[18F\]NIDF or any of its excipients;
2. Incapable of providing written informed consent or lacking a legally authorized representative (LAR) to provide informed consent ;
3. Unwilling or unable to undergo PET scans tracer injections;
4. Any condition that, in the Investigator's opinion, could increase the risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., renal or liver failure, advanced cancer);
5. Received an experimental drug or device within 1 month (whose efficacy or safety is unclear);
6. Have other serious neurological disorders, or gastrointestinal, cardiovascular, liver, kidney, blood system, tumor, endocrine, respiratory, immune deficiency, and other serious diseases;
7. Women who are currently pregnant or breastfeeding.

Where it's running

  • The First Affiliated Hospital of University of Science and Technology of China
    Hefei, Anhui, China
    Recruiting
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
    Recruiting
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.